Advancing Medicines for Hormone Driven Cancers
Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers.
Apristor for PR+ Cancers
Apristor is an investigational medicine for breast, ovarian, and endometrial cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor (PR).
New York, NY
American Society of Clinical Oncology (ASCO)
May 31-June 4